Syncom Formulations (India)'s Q2 FY 2025-26 Quarterly Results

Result Summary

• Syncom Formulations (India) Ltd reported a 3.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 19.3%.
• Its expenses for the quarter were up by 2.2% QoQ and 14.5% YoY.
• The net profit increased 5.4% QoQ and increased 49.4% YoY.
• The earnings per share (EPS) of Syncom Formulations (India) Ltd stood at 0.18 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Syncom Formulations (India) Ltd is a company engaged in the pharmaceutical industry, primarily involved in manufacturing and marketing a wide range of pharmaceutical formulations. The company's product portfolio includes tablets, capsules, liquid orals, ointments, and injectable products. The company serves both domestic and international markets, focusing on providing quality healthcare products. While specific recent major developments are not provided, the company operates in a highly competitive industry characterized by ongoing research and development, regulatory compliance, and market expansion efforts.

Revenue

For the quarter ending Q2FY26, Syncom Formulations (India) Ltd achieved a total income of ₹126.97 crores. This marks a quarter-over-quarter (QoQ) increase of 3.3% compared to Q1FY26, where the total income was ₹122.94 crores. Year-over-year (YoY), the total income showed a notable growth of 19.3% from Q2FY25, where the income stood at ₹106.46 crores. These figures highlight the company's revenue growth over both the short and long term, reflecting its performance in generating sales and other forms of income during the specified period.

Profitability

In Q2FY26, Syncom Formulations (India) Ltd reported a profit before tax of ₹22.04 crores, which is an increase of 8.6% QoQ from ₹20.29 crores in Q1FY26. On a YoY basis, the profit before tax increased significantly by 48.4% from ₹14.85 crores in Q2FY25. After accounting for taxes, the profit after tax for Q2FY26 was ₹16.60 crores, up 5.4% QoQ from ₹15.75 crores in Q1FY26 and 49.4% YoY from ₹11.11 crores in Q2FY25. These figures underscore the company's ability to manage costs effectively and improve profitability over time.

Operating Metrics

The total expenses of Syncom Formulations (India) Ltd for Q2FY26 were ₹104.93 crores, reflecting a QoQ increase of 2.2% from ₹102.68 crores in Q1FY26. Compared to the same quarter last year (Q2FY25), expenses rose by 14.5% from ₹91.61 crores. The tax expense for Q2FY26 was ₹5.44 crores, which is a significant QoQ increase of 19.8% from ₹4.54 crores in Q1FY26 and a YoY rise of 45.5% from ₹3.74 crores in Q2FY25. Earnings per share (EPS) for Q2FY26 was reported at ₹0.18, marking a decrease of 14.3% QoQ from ₹0.21 recorded in Q1FY26, but an increase of 12.5% YoY from ₹0.16 in Q2FY25. These operating metrics provide insight into the company's financial health and operational efficiency over the observed periods.